Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
J&J’s Tecvayli/Darzalex nod was the second under a new priority voucher scheme.
Rinzimetostat efficacy wanes further as the company moves into phase 3.
The group wants to improve on its own Welireg in a new phase 3 trial.
Replimune gets a second chance, while Sarclisa could go subcutaneous.
After a delay, the Alpha-3 study faces an April futility analysis.
A first-in-human trial of PRT12396 starts next month.
